Apimeds Pharmaceuticals US, Inc. (APUS)
Score window: Apr. 15, 2025 to Apr. 14, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| May. 5, 2025 | CORRESP | Neutral/Informational | High | Apimeds Pharmaceuticals US, Inc. has submitted a request to the SEC for the acceleration of the effectiveness of their Registration Statement on Form S-1. The company aims for the… | Read Filing EDGAR |
| May. 5, 2025 | CORRESP | Neutral/Informational | Moderate | The correspondence from D. Boral Capital LLC to the SEC requests the acceleration of the effective date for Apimeds Pharmaceuticals US, Inc.'s Registration Statement on Form S-1. … | Read Filing EDGAR |
| May. 5, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has completed its review of Apimeds Pharmaceuticals US, Inc.'s Form 10-K for the fiscal year ended December 31, 2024. The correspondence emphasizes that the responsibility… | Read Filing EDGAR |
| May. 1, 2025 | CORRESP | Concern from SEC | Moderate | Apimeds Pharmaceuticals US, Inc. is responding to a comment letter from the SEC regarding their Post-Effective Amendment No. 1 to Registration Statement on Form S-1. The company a… | Read Filing EDGAR |
| May. 1, 2025 | CORRESP | Concern from SEC | High | Apimeds Pharmaceuticals US, Inc. has responded to a comment letter from the SEC regarding their Form 10-K for the fiscal year ended December 31, 2024. The SEC raised concerns abou… | Read Filing EDGAR |
| May. 1, 2025 | UPLOAD | Concern from SEC | High | The SEC has conducted a limited review of Apimeds Pharmaceuticals' Form 10-K for the fiscal year ended December 31, 2024, focusing on the financial statements and related disclosu… | Read Filing EDGAR |
| Apr. 30, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed Apimeds Pharmaceuticals US, Inc.'s post-effective amendment to their registration statement and has raised several comments that need to be addressed. Notably… | Read Filing EDGAR |